Analyst Expectations for Alnylam Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) has received a mix of bullish and indifferent analyst ratings in the last quarter. In the last 3 months, 11 analysts have offered 12-month price targets for the company, with an average price target of $263.18, a 3.42% decrease from the previous average price target of $272.50.

July 25, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mixed analyst ratings and a decreased average price target could lead to uncertainty among investors, potentially impacting Alnylam Pharmaceuticals' stock price.
Analyst ratings can influence investor sentiment and thus, the stock price. The mixed ratings and decreased price target for Alnylam Pharmaceuticals indicate uncertainty, which could lead to stock price volatility.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100